

**TUESDAY, JUNE 25, 2013**

---

**TOPIC: The Promise of Precision Medicine: Implementing Biomarkers Along the Continuum - Optimizing Discovery, Development and Patient Care**

**SPEAKERS:** **Daniel Chin, PhD**, Senior Principal Scientist, Roche  
**Iya Khalil, PhD**, Executive Vice President and Co-Founder, GNS Healthcare  
**Vince Miller, MD**, Senior Vice President, Clinical Development, Foundation Medicine  
**Amelia Warner, PharmD**, Head, Clinical Pharmacogenomics and Clinical Specimen Management, Merck

**MODERATORS:** **Jeffrey M. Bockman, PhD**, Vice President, Defined Health  
**Michael C. Rice**, Senior Consultant, Defined Health

When many people hear the term *personalized medicine* they usually automatically envision a test being done on a patient that will enable the decision about whether or not to use a particular pharmaceutical product. However, the utility and benefits of linking specific biomarker “signatures” extend from the very initial target discovery and validation stages, through improved clinical trial designs that offer de-risking of the development pathway, to expedited regulatory review, and ultimately, to allowing the identification of the right drug for the right patient, in the right dose, at the right time point.

This program features a panel of industry experts who will share their experience across the “precision medicine” spectrum.

Topics of discussion include:

- Advances and challenges in the application of personalized medicine in oncology and non-oncology indications
- Examples of how translational medicine, using predictive biomarkers, is enabling stratification of patients in clinical research
- The regulatory and other implications for collecting genomic samples and analyzing data from multinational clinical trial sites
- The role of “big data” and emerging technologies in the future of precision medicine